Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH)

Current studies have shown that remote ischemic conditioning can improve vascular endothelial function, inhibit sympathetic nervous system activity and regulate immune and inflammatory reactions. Thus it may exert anti-hypertensive effects through multiple mechanisms. The purpose of this study is to investigate the efficacy and safety of remote ischemic conditioning on blood pressure patients with essential hypertension.

Inclusion criteria

• Age≥18 years, regardless of sex;
• Patients with systolic blood pressure ≥140mmHg with or without taking oral antihypertensive drugs
• Signed and dated informed consent is obtained

Exclusion criteria

• Secondary hypertension;
• Clinical blood pressure ≥ 180/110 mmHg or 24-hour mean arterial pressure ≥ 170/100 mmHg;
• Severe organ dysfunction or failure;
• Severe hematologic disorders or significant coagulation abnormalities;
• History of atrial fibrillation or myocardial infarction within 6 months;
• Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
• Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc; ;
• Pregnant or lactating women;
• Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment;
• Other conditions that the researchers think are not suitable for the project.